A new study from Oxford University shows people under the age of 40 are at higher risk of developing myocarditis after the second dose of Moderna's Wuhan coronavirus vaccine than they are of developing it through natural infection.
A case series published in @NatureMedicine shows an increased risk of myocarditis after receiving the Astra-Zeneca-Oxford, Pfizer-BioNTech and the Moderna COVID-19 vaccines, but SARS-CoV-2 infection carried a greater risk of myocarditis. https://t.co/6y7pZlJN70 pic.twitter.com/cBlKz9sUkg— Nature Portfolio (@NaturePortfolio) December 14, 2021
Dr. Vinay Prasad went through the data, calling the revelation a bombshell, and offered a number of solutions.
"In under 40-year-old people...dose two of Moderna has exceeded the risk of myocarditis after infection with a second dose," Prasad said. "There have been many people who have been reluctant to take serious the risks of myocarditis after the Moderna product."
"If you're under 40 and if you pool men and women together, there is more myocarditis associated with dose two of Moderna than there is with an infection. That is a bombshell finding," he continued.
The study came just days before the CDC recommended Moderna and Pfizer over the Johnson & Johnson vaccine, which it says has serious but rare blood clotting side effects.
A Centers for Disease Control and Prevention panel on Thursday voted 15-0 to recommend that mRNA Wuhan coronavirus vaccines made by Pfizer and Moderna take preference over Johnson & Johnson's single-dose shot for most Americans.https://t.co/tqVhg7B4gz— Spencer Brown (@itsSpencerBrown) December 16, 2021